



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#9
L.P.
91690

Applicants: Campbell Rogers, Elazer R. Edelman and Daniel I. Simon

Serial No.: 08/823,999

Group Art Unit: 1644

Filed: March 25, 1997

Examiner: Phillip Gambel

For: *MODULATION OF VASCULAR HEALING BY INHIBITION OF LEUKOCYTE
ADHESION AND FUNCTION*

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

Responsive to the Office Action mailed July 28, 1998, applicants elect to prosecute group I, claims 1-12, with traverse, and elect as the species A, Mac-1, and B, an antibody. A Petition for an Extension of Time for one month, up to and including September 27, 1998, is enclosed with this response. It is believed no other additional fees are due. However, should a fee be required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 01-2507. Applicants enclose a duplicate of this document to facilitate this process.

Claims 1-17 were divided into two groups, group I, claims 1-12, drawn to methods of inhibiting restenosis, and group II, claims 13-17, drawn to compositions for use in the method of group I. Applicants elect group I with traverse. It is believed that it would

U.S.S.N.: 08/823,999
Filed: March 25, 1997
RESPONSE TO RESTRICTION REQUIREMENT




represent no additional effort to search group II, since the compositions must be searched in order to search the methods of use.

Applicants were also required to elect a species where the integrin specificity is one of Mac-1, LFA-1, p150,95, CD11d/CD18, ICAM-1, fibrinogen, C3bi, or factor X, and where the composition is one of an antibody, molecule which inhibit interin or ligand expression, or integrin/ligand-derived peptides or peptidomimetics. Applicants elect Mac-1 and antibodies, with the understanding that the generic claims will be searched on the merits once the species are determined to be allowable.

Please note that an Information Disclosure Statement was mailed April 27, 1998, in this application.

Favorable consideration of claims 1-17 is earnestly solicited.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284


Date: September 1, 1998
ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8794
(404) 873-8797 (fax)

U.S.S.N.: 08/823,999
Filed: March 25, 1997
RESPONSE TO RESTRICTION REQUIREMENT



Certificate of Mailing under 37 CFR § 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.



Jean Hicks

Date: September 1, 1998